324 related articles for article (PubMed ID: 10412949)
1. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
Nielsen LL
Oncol Rep; 2000; 7(6):1191-6. PubMed ID: 11032912
[TBL] [Abstract][Full Text] [Related]
5. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
6. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
7. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Heise C; Lemmon M; Kirn D
Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
10. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.
Nielsen LL
Oncol Rep; 2000; 7(1):151-5. PubMed ID: 10601610
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.
Nielsen LL; Dell J; Maxwell E; Armstrong L; Maneval D; Catino JJ
Cancer Gene Ther; 1997; 4(2):129-38. PubMed ID: 9080122
[TBL] [Abstract][Full Text] [Related]
15. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
[TBL] [Abstract][Full Text] [Related]
17. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma.
Nakashima T; Sun SY; Lotan R; Fujiwara T; Yasumatsu R; Komiyama S; Clayman GL
Laryngoscope; 2001 Aug; 111(8):1459-64. PubMed ID: 11568584
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model.
Yoo GH; Subramanian G; Ezzat WH; Tulunay OE; Tran VR; Lonardo F; Ensley JF; Kim H; Won J; Stevens T; Zumstein LA; Lin HS
Am J Otolaryngol; 2010; 31(2):78-83. PubMed ID: 20015717
[TBL] [Abstract][Full Text] [Related]
19. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]